<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33431491</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>11</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Study protocol of RESCUE-ALS: A Phase 2, <u>r</u>andomised, double-blind, placebo-controlled study in <u>e</u>arly <u>s</u>ymptomatic amyotrophic lateral sclerosis patients to assess bioenergetic <u>c</u>atalysis with CNM-A<u>u</u>8 as a mechanism to slow diseas<u>e</u> progression.</ArticleTitle><Pagination><StartPage>e041479</StartPage><MedlinePgn>e041479</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e041479</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2020-041479</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Amyotrophic lateral sclerosis (ALS) is an adult-onset, progressive and universally fatal neurodegenerative disorder. In Europe, Australia and Canada, riluzole is the only approved therapeutic agent for the treatment of ALS, while in the USA, riluzole and edaravone have been approved by the Food and Drug Administration (FDA) . Neither riluzole nor edaravone treatment has resulted in substantial disease-modifying effects. There is, therefore, an urgent need for drugs that result in safe and effective treatment. Here, we present the design and rationale for the phase 2 RESCUE-ALS study, investigating the novel nanocatalytic drug, CNM-Au8, as a therapeutic intervention that enhances the metabolic and energetic capacity of motor neurones. CNM-Au8 is an aqueous suspension of clean-surfaced, faceted gold nanocrystals that have extraordinary catalytic capabilities, that enhance efficiencies of key metabolic reactions, while simultaneously reducing levels of reactive oxygen species. This trial utilises a novel design by employing motor unit number index (MUNIX), measured by electromyography, as a quantitative measure of lower motor neurone loss and as an early marker of ALS disease progression.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">This is a multicentre, randomised, double-blind, parallel group, placebo-controlled study of the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in ALS patients. Patients will be randomised 1:1 to either receive 30 mg of CNM-Au8 once daily or matching placebo over a 36-week double-blind treatment period. Efficacy will be assessed as the change in motor neurone loss as measured by electromyography (eg, MUNIX, the primary endpoint; and secondary endpoints including MScanFit, motor unit size index, Split Hand Index, Neurophysiology Index). Exploratory endpoints include standard clinical and quality of life assessments.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">RESCUE-ALS was approved by the Western Sydney Local Health District Human Research Ethics Committee (Ethics Ref: 2019/ETH12107). Results of the study will be submitted for publication in a peer-reviewed journal.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">NCT04098406.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vucic</LastName><ForeName>Steve</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8323-873X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Westmead Hospital and Western Clinical School, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-9054-026X</Identifier><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Parvathi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Westmead Hospital and Western Clinical School, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huynh</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rynders</LastName><ForeName>Austin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clene Nanomedicine, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0000-0003-3217-354X</Identifier><AffiliationInfo><Affiliation>Clene Nanomedicine, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glanzman</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6267-4006</Identifier><AffiliationInfo><Affiliation>Clene Nanomedicine, Salt Lake City, Utah, USA robert@clene.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hotchkin</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Clene Nanomedicine, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04098406</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002384" MajorTopicYN="N">Catalysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult neurology</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">motor neurone disease</Keyword><Keyword MajorTopicYN="N">neuromuscular disease</Keyword></KeywordList><CoiStatement>Competing interests: AR, KSH, RG and MTH are full-time employees and hold stock or options in Clene Nanomedicine. SV and MK are directors of companies that hold equity in Clene Nanomedicine. SV, MK and their respective institutions receive research funding support for the RESCUE-ALS study from Clene Nanomedicine. MK is Editor-in-Chief of the Journal of Neurology, Neurosurgery and Psychiatry (BMJ Publishers, UK).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33431491</ArticleId><ArticleId IdType="pmc">PMC7802642</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2020-041479</ArticleId><ArticleId IdType="pii">bmjopen-2020-041479</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. Lancet 2011;377:942&#x2013;55. 10.1016/S0140-6736(10)61156-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, et al. . Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008;119:497&#x2013;503. 10.1016/j.clinph.2007.09.143</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011;7:639&#x2013;49. 10.1038/nrneurol.2011.153</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.153</ArticleId><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur KC, Calvo A, Price TR, et al. . Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun 2016;7:12408. 10.1038/ncomms12408</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman M, Zinman L. The economic impact of amyotrophic lateral sclerosis: a systematic review. Expert Rev Pharmacoecon Outcomes Res 2015;15:439&#x2013;50. 10.1586/14737167.2015.1039941</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737167.2015.1039941</ArticleId><ArticleId IdType="pubmed">25924979</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Factor-Litvak P, Andrews H, et al. . Als multicenter cohort study of oxidative stress (ALS Cosmos): study methodology, recruitment, and baseline demographic and disease characteristics. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:192&#x2013;203. 10.3109/21678421.2013.864312</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.864312</ArticleId><ArticleId IdType="pmc">PMC4310702</ArticleId><ArticleId IdType="pubmed">24564738</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Lin CS-Y, Cheah BC, et al. . Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain 2013;136:1361&#x2013;70. 10.1093/brain/awt085</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt085</ArticleId><ArticleId IdType="pubmed">23616585</ArticleId></ArticleIdList></Reference><Reference><Citation>Noto Y-I, Shibuya K, Vucic S, et al. . Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis. Expert Rev Neurother 2016;16:1147&#x2013;54. 10.1080/14737175.2016.1197774</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2016.1197774</ArticleId><ArticleId IdType="pubmed">27314534</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 2019;39:733&#x2013;48. 10.1002/med.21528</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Al-Chalabi A, Chio A, et al. . Genetic screening in sporadic ALS and FTD. J Neurol Neurosurg Psychiatry 2017;88:1042&#x2013;4. 10.1136/jnnp-2017-315995</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315995</ArticleId><ArticleId IdType="pmc">PMC5740553</ArticleId><ArticleId IdType="pubmed">28642287</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, et al. . Als genetics, mechanisms, and therapeutics: where are we now? Front Neurosci 2019;13:1310. 10.3389/fnins.2019.01310</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008;131:1540&#x2013;50. 10.1093/brain/awn071</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn071</ArticleId><ArticleId IdType="pubmed">18469020</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T, De Bock K, Van Den Bosch L. Energy metabolism in ALS: an underappreciated opportunity? Acta Neuropathol 2018;135:489&#x2013;509. 10.1007/s00401-018-1835-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1835-x</ArticleId><ArticleId IdType="pmc">PMC5978930</ArticleId><ArticleId IdType="pubmed">29549424</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amico E, Factor-Litvak P, Santella RM, et al. . Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med 2013;65:509&#x2013;27. 10.1016/j.freeradbiomed.2013.06.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.06.029</ArticleId><ArticleId IdType="pmc">PMC3859834</ArticleId><ArticleId IdType="pubmed">23797033</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat P-F, Ludolph AC, et al. . Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 2011;10:75&#x2013;82. 10.1016/S1474-4422(10)70224-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefera TW, Borges K. Metabolic dysfunctions in amyotrophic lateral sclerosis pathogenesis and potential metabolic treatments. Front Neurosci 2016;10:611. 10.3389/fnins.2016.00611</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2016.00611</ArticleId><ArticleId IdType="pmc">PMC5222822</ArticleId><ArticleId IdType="pubmed">28119559</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Irish M, Piguet O, et al. . Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. Lancet Neurol 2016;15:332&#x2013;42. 10.1016/S1474-4422(15)00380-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00380-4</ArticleId><ArticleId IdType="pubmed">26822748</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Ke YD, Vucic S, et al. . Physiological changes in neurodegeneration - mechanistic insights and clinical utility. Nat Rev Neurol 2018;14:259&#x2013;71. 10.1038/nrneurol.2018.23</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2018.23</ArticleId><ArticleId IdType="pubmed">29569624</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemann FR, Manfredi G, Mawrin C, et al. . Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem 2002;80:616&#x2013;25. 10.1046/j.0022-3042.2001.00731.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0022-3042.2001.00731.x</ArticleId><ArticleId IdType="pubmed">11841569</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson AP, Zhang JZ, Titus HE, et al. . Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis. Sci Rep 2020;10:10. 10.1038/s41598-020-58709-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-58709-w</ArticleId><ArticleId IdType="pmc">PMC7010780</ArticleId><ArticleId IdType="pubmed">32041968</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan BA, Pehar M, Sharma DR, et al. . Enhancing NAD+ salvage pathway reverts the toxicity of primary astrocytes expressing amyotrophic lateral sclerosis-linked mutant superoxide dismutase 1 (SOD1). J Biol Chem 2016;291:10836&#x2013;46. 10.1074/jbc.M115.698779</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.698779</ArticleId><ArticleId IdType="pmc">PMC4865928</ArticleId><ArticleId IdType="pubmed">27002158</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan BA, Pehar M, Killoy KM, et al. . Enhanced SIRT6 activity abrogates the neurotoxic phenotype of astrocytes expressing ALS-linked mutant SOD1. Faseb J 2019;33:7084&#x2013;91. 10.1096/fj.201802752R</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201802752R</ArticleId><ArticleId IdType="pmc">PMC6529338</ArticleId><ArticleId IdType="pubmed">30841754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Zhu L, Qiu W, et al. . Nicotinamide Riboside Enhances Mitochondrial Proteostasis and Adult Neurogenesis through Activation of Mitochondrial Unfolded Protein Response Signaling in the Brain of ALS SOD1G93A Mice. Int J Biol Sci 2020;16:284&#x2013;97. 10.7150/ijbs.38487</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.38487</ArticleId><ArticleId IdType="pmc">PMC6949147</ArticleId><ArticleId IdType="pubmed">31929756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmar B, Lu C-H, Greensmith L. The role of heat shock proteins in amyotrophic lateral sclerosis: the therapeutic potential of arimoclomol. Pharmacol Ther 2014;141:40&#x2013;54. 10.1016/j.pharmthera.2013.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2013.08.003</ArticleId><ArticleId IdType="pubmed">23978556</ArticleId></ArticleIdList></Reference><Reference><Citation>KS H, Zhang JZ, Richard J-P, et al. . Redox-enhancing nanocatalysis improves motor neuron survival in vitro and SOD1 mouse motor function and survival in vivo. Perth, Australia, 2019.</Citation></Reference><Reference><Citation>Neuwirth C, Barkhaus PE, Burkhardt C, et al. . Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the motor unit number index (MUNIX): a 15-month longitudinal multicentre trial. J Neurol Neurosurg Psychiatry 2015;86:1172&#x2013;9. 10.1136/jnnp-2015-310509</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310509</ArticleId><ArticleId IdType="pubmed">25935892</ArticleId></ArticleIdList></Reference><Reference><Citation>Alix JJP, Neuwirth C, Gelder L, et al. . Assessment of the reliability of the motor unit size index (MUSIX) in single subject "round-robin" and multi-centre settings. Clin Neurophysiol 2019;130:666&#x2013;74. 10.1016/j.clinph.2019.01.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2019.01.020</ArticleId><ArticleId IdType="pubmed">30870802</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekestein WA, Schelhaas HJ, van Putten MJAM, et al. . Motor unit number index (MUNIX) versus motor unit number estimation (MUNE): a direct comparison in a longitudinal study of ALS patients. Clin Neurophysiol 2012;123:1644&#x2013;9. 10.1016/j.clinph.2012.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2012.01.004</ArticleId><ArticleId IdType="pubmed">22321299</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Loy CT, Menon P, et al. . Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: a systematic review using individual patient data. Clin Neurophysiol 2016;127:2684&#x2013;91. 10.1016/j.clinph.2016.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2016.04.005</ArticleId><ArticleId IdType="pubmed">27212114</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashihara M, Menon P, van den Bos M, et al. . Reproducibility of motor unit number index and MScanFit motor unit number estimation across intrinsic hand muscles. Muscle Nerve 2020;62:192&#x2013;200. 10.1002/mus.26839</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26839</ArticleId><ArticleId IdType="pubmed">32077117</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandedkar SD, Barkhaus PE, St&#xe5;lberg EV, et al. . Motor unit number index: guidelines for recording signals and their analysis. Muscle Nerve 2018;58:374&#x2013;80. 10.1002/mus.26099</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26099</ArticleId><ArticleId IdType="pubmed">29427557</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen AB, Bostock H, Fuglsang-Frederiksen A, et al. . Reproducibility, and sensitivity to motor unit loss in amyotrophic lateral sclerosis, of a novel MUNE method: MScanFit MUNE. Clin Neurophysiol 2017;128:1380&#x2013;8. 10.1016/j.clinph.2017.03.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2017.03.045</ArticleId><ArticleId IdType="pubmed">28461135</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostock H. Estimating motor unit numbers from a CMAP scan. Muscle Nerve 2016;53:889&#x2013;96. 10.1002/mus.24945</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24945</ArticleId><ArticleId IdType="pubmed">26479267</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen RS, Bostock H, Tan SV, et al. . MScanFit motor unit number estimation (MScan) and muscle velocity recovery cycle recordings in amyotrophic lateral sclerosis patients. Clin Neurophysiol 2019;130:1280&#x2013;8. 10.1016/j.clinph.2019.04.713</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2019.04.713</ArticleId><ArticleId IdType="pubmed">31163374</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheah BC, Vucic S, Krishnan AV, et al. . Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. Amyotroph Lateral Scler 2011;12:33&#x2013;8. 10.3109/17482968.2010.531742</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.531742</ArticleId><ArticleId IdType="pubmed">21271790</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Kiernan MC, Yiannikas C, et al. . Split-Hand index for the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol 2013;124:410&#x2013;6. 10.1016/j.clinph.2012.07.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2012.07.025</ArticleId><ArticleId IdType="pubmed">23017503</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, et al. . Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry 2016;87:628&#x2013;32. 10.1136/jnnp-2015-310998</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310998</ArticleId><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>